FDA official logo
GSRS logoPFDA official logo

DISITAMAB VEDOTIN

UNII:RB3U3A1S27
Formula:
Preferred Substance Name:DISITAMAB VEDOTIN

  • 2136633-23-1
  • DISITAMAB VEDOTIN [INN]
  • DISITAMAB VEDOTIN [USAN]
  • DISITAMAB VEDOTIN [WHO-DD]
  • IMMUNOGLOBULIN G1, ANTI-(HUMAN TYROSINE KINASE RECEPTOR ERBB2) (HUMAN-MUS MUSCULUS MONOCLONAL RC48-270A4023 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL RC48-270A4023 .KAPPA.-CHAIN, DIMER, THIOETHER WITH N-(((4-((N-(6-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-1-OXOHEXYL)-L-VALYL-N5-(AMINOCARBONYL)-L-ORNITHYL)AMINO)PHENYL)METHOXY)CARBONYL)-N-METHYL-L-VALYL-N-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1R,2S)-2-HYDROXY-1-METHYL-2-PHENYLETHYL)AMINO)-1-METHOXY-2-METHYL-3-OXOPROPYL)-1-PYRROLIDINYL)-2-METHOXY-1-((1S)-1-METHYLPROPYL)-4-OXOBUTYL)-N-METHYL-L-VALINAMIDE
  • IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY CONJUGATED TO AURISTATIN E; GAMMA1 HEAVY CHAIN HUMANIZED (1-445) (VH (HOMO SAPIENS IGHV1-69-2*01 (83.5%) -(IGHD) -IGHJ1*01 (92.9%)) (8.8.8) (1-115) -HOMO SAPIENS IGHG1*03V, G1M3>G1M17, NG1M1 (CH1 R120>K (212) (116-213), HINGE (214-228), CH2 (229-338), CH3 E12 (354), M14 (357) (339-443), CHS (444-445)) (116-445)) (218-212')-DISULFIDE WITH KAPPA LIGHT CHAIN HUMANIZED (1'-212') (V-KAPPA (HOMO SAPIENS IGKV1-39*01 (83.3%) -IGKJ4*01 (100%))(6.3.7) (1'-105') -HOMO SAPIENS IGKC*01 (100%) KM3 A45.1 (151), V101 (189) (106'-212')); DIMER (224-224'':227-227'')-BISDISULFIDE; CONJUGATED ON AN AVERAGE OF 4 CYSTEINYL TO MONOMETHYLAURISTATIN E (MMAE), VIA A CLEAVABLE MALEIMIDOCAPROYL-VALYL-CITRULLINYL-PAMINOBENZYLOXYCARBONYL (MC-VAL-CIT-PABC) TYPE LINKER
  • RC48-ADC




UNII - RB3U3A1S27 | UNII Search Service